Therapeutically active compounds and their methods of use

Inventors

Popovici-Muller, Janeta • Lemieux, Rene M. • Travins, Jeremy • Cai, Zhenwei • Cui, DaWei • Zhou, Ding

Assignees

PHARMARESOURCES (SHANGHAI) CO Ltd • Servier Pharmaceuticals LLC

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11667673-B2

Patent

Publication Date

2023-06-06

Expiration Date


Abstract

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Core Innovation

The invention provides a method of treating myelodysplastic syndrome characterized by having an IDH1 mutation in a patient in need thereof. The method comprises administering a therapeutically effective amount of (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide, or a pharmaceutically acceptable salt or hydrate thereof. The claims further identify the target mutation as an IDH1 R132X mutation, including R132H or R132C variants.

The disclosed subject matter provides compounds and pharmaceutical compositions functioning as inhibitors of mutant IDH enzymes associated with 2-hydroxyglutarate production. These pyrrolidinone carboxamide analogs incorporate fluorinated cycloalkyl, chlorophenyl, cyano-substituted heteroaryl, and fluoropyridinyl moieties. The disclosure details mutant IDH inhibitors evaluated across in vitro and cellular assays, including measurement of 2-hydroxyglutarate suppression in cell lines.

Claims Coverage

The claims comprise one independent claim and two dependent claims, representing three inventive features.

Treatment of IDH1-mutated myelodysplastic syndrome

The independent claim provides a method of treating myelodysplastic syndrome characterized by an IDH1 mutation in a patient in need thereof, comprising administering a therapeutically effective amount of (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide, or a pharmaceutically acceptable salt or hydrate thereof.

IDH1 R132X mutation

A dependent claim specifies that the IDH1 mutation is an IDH1 R132X mutation.

IDH1 R132H or R132C mutation

A dependent claim specifies that the IDH1 mutation is an R132H or R132C mutation.

The claims cover methods of treating IDH1-mutated myelodysplastic syndrome using the specified compound or its pharmaceutically acceptable salt or hydrate, with dependent claims refining the mutation requirement to IDH1 R132X, R132H, or R132C.

Stated Advantages

Not explicitly described in patent.

Documented Applications

Treatment of myelodysplastic syndrome (MDS) characterized by having an IDH1 mutation, including IDH1 R132X, R132H, or R132C mutation variants.

Use of Formula I compounds to inhibit mutant IDH1 or IDH2 and treat cancer.

Monitoring treatment through 2-hydroxyglutarate (2HG) levels.

Potential combination therapies for cancer treatment.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.